Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

Other

Boehringer Mannheim Gmbh

F. Hoffmann-la Roche Ag

Konrad Honold

Stefan Scheiblich

Wolfgang Schaefer

Anne Stern

Johannes Auer

Michael Brandt

Hans Koll

Birgit Masjost

Klaus Kaluza

Petra Rueger

Reinhard Franze

Ulrich Pessara

Hubert Hertenberger

Thomas Von Hirschheydt

Richard Engh

Manfred Schwaiger

Christian Klein

Frederick Arthur Brookfield

Christos Tsaklakidis

Edward Andrew Boyd

Kin-Chun Thomas Luk

Kurt Lang

Georg Tiefenthaler

Edgar Voss

Lothar Kling

Nikolaos Dimoudis

Angelika Esswein

Jianping Cai

Ulrike Leser

Jonathan Gridley

Raymond Lau

Raimund Sprenger

Hilke Sudergat

Oliver Tonn

Thomas Holtschke

Jane Paul

Carl Roeschlaub

Alan Whittle

Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors

Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

7H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors

Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer. 

Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents

The present invention relates to novel amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, to a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The present derivatives are new compounds of the general formula (I). 

Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents

Benzamide derivatives, their manufacture and use as pharmaceutical agents

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors

The present invention relates to novel amide derivatives of 7-amino-3-phenyl dihydropyrimido[4,5-d]pyrimidinones, to a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The present derivatives are new compounds of the general formula (I). 

Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents

A method for the recombinant production and purification of a protein kinase selected from the group consisting of tyrosine protein kinases and serine/threonine kinases by expressing a nucleic acid encoding said kinase in a microbial host cell, forming inclusion bodies containing said kinase, isolating, solubilizing, naturing, and purifying said kinase wherein said purification is performed by hydrophobic interaction with an hydrophobic adsorbent under conditions whereby at least 70% of said protein kinase are not bound to said adsorbent and the protein kinase not bound to said adsorbent is recovered.

Method for the recombinant production and purification of protein kinases

The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention concerns a process for the production of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO gene in human cells as well as a process for the large-scale production of EPO in human cells.

Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereof

The invention describes compounds of the general formula I a process for their manufacture, compositions containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. These compounds show activity as protein kinase inhibitors, in particular src family tyrosine kinase inhibitors, and may therefore be useful for the treatment of diseases mediated by said tyrosine kinases.

Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives

The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO in human cells, and a method for the large technical production of EPO in human cells.

Preparation of erythropoietin by endogenous gene activation

Compounds of the general formula (I) are presented which arevaluable therapeutics for the treatment of cancer and cancer related diseases.

Imidazole derivatives and their use as pharmaceutical agents

The invention describes compounds of the general formula I a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The compounds show activity as protein kinase inhibitors, in particular src family tyrosine kinase inhibitors, and may therefore be useful for the treatment of diseases mediated by said tyrosine kinases.

Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents

Compounds of formula I are described. These compounds are protein kinase inhibitors, in particular they inhibit the src family tyrosine kinases. Thus, these compounds are useful for the treatment of diseases mediated by src tyrosine kinases, including cell proliferative disorders such as cancer. Also described are methods of making and using compounds of formula I as well as pharmaceutical compositions containing these compounds.

Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives

Growing community of inventors

Penzberg, Germany

Konrad Honold